

Resource Summary Report

Generated by [RRID](#) on Sep 2, 2026

RMG-I

RRID:CVCL_1662

Type: Cell Line

Proper Citation

RRID:CVCL_1662

Cell Line Information

URL: https://web.expasy.org/cellosaurus/CVCL_1662

Proper Citation: RRID:CVCL_1662

Description: Cell line RMG-I is a Cancer cell line with a species of origin Homo sapiens (Human)

Sex: Female

Disease: Ovarian clear cell adenocarcinoma

Defining Citation: [PMID:3154025](#), [PMID:8980248](#), [PMID:11330945](#), [PMID:12417041](#), [PMID:17671176](#), [PMID:20081105](#), [PMID:20164919](#), [PMID:20215515](#), [PMID:22460905](#), [PMID:22705003](#), [PMID:23430509](#), [PMID:23839242](#), [PMID:24023729](#), [PMID:25485619](#), [PMID:25846456](#), [PMID:25877200](#), [PMID:25960936](#), [PMID:25984343](#), [PMID:26589293](#), [PMID:27397505](#), [PMID:28196595](#), [PMID:28273451](#), [PMID:30485824](#), [PMID:30894373](#), [PMID:30971826](#), [PMID:31068700](#), [PMID:35839778](#)

Comments: Population: Japanese., Part of: MD Anderson Cell Lines Project., Part of: COSMIC cell lines project., Part of: Cancer Dependency Map project (DepMap) (includes Cancer Cell Line Encyclopedia - CCLE).

Category: Cancer cell line

Organism: Homo sapiens (Human)

Name: RMG-I

Synonyms: RMGI, RMG1, RMG-1

Cross References: BTO:BTO_0004930, CLO:CLO_0037103, EFO:EFO_0006746, ArrayExpress:E-MTAB-783, ArrayExpress:E-MTAB-2706, ArrayExpress:E-MTAB-2770, ArrayExpress:E-MTAB-3610, BioGRID_ORCS_Cell_line:1000, BioSample:SAMN03471003, BioSample:SAMN10988355, cancercellines:CVCL_1662,

Cell_Model_Passport:SIDM00352, CGH-DB:336-2, CGH-DB:9362-4, ChEMBL-Cells:ChEMBL3308778, ChEMBL-Targets:ChEMBL1075564, Cosmic:909699, Cosmic:931360, Cosmic:945377, Cosmic:1152556, Cosmic:1223319, Cosmic:1328068, Cosmic:1708378, Cosmic:1889262, Cosmic:2482708, Cosmic:2582799, Cosmic-CLP:909699, DepMap:ACH-000719, EGA:EGAS00001000610, EGA:EGAS00001000978, GDSC:909699, GEO:GSM416682, GEO:GSM659403, GEO:GSM827210, GEO:GSM887544, GEO:GSM888627, GEO:GSM1001429, GEO:GSM1001430, GEO:GSM1176283, GEO:GSM1340592, GEO:GSM1670383, GEO:GSM2475004, IARC_TP53:21289, JCRB:FDSC0027, JCRB:IFO50315, JCRB:JCRB0172, LiGeA:CCLE_443, LINCS_LDP:LCL-1805, PharmacDB:RMGI_1320_2019, PRIDE:PXD030304, Progenetix:CVCL_1662, PubChem_Cell_line:CVCL_1662, Wikidata:Q54950664

ID: CVCL_1662

Record Creation Time: 20220427T221502+0000

Record Last Update: 20260829T235745+0000

Ratings and Alerts

No rating or validation information has been found for RMG-I.

Warning: Discontinued: JCRB; FDSC0027

Population: Japanese., Part of: MD Anderson Cell Lines Project., Part of: COSMIC cell lines project., Part of: Cancer Dependency Map project (DepMap) (includes Cancer Cell Line Encyclopedia - CCLE).

Data and Source Information

Source: [Cellosaurus](#)

Usage and Citation Metrics

We found 16 mentions in open access literature.

Listed below are recent publications. The full list is available at [RRID](#) .

Sakaguchi-Mukaida H, et al. (2026) Metabolome analysis identified exogenous cholesterol within lipid rafts that activate the Akt/mTOR signaling pathway in epithelial ovarian cancer. International journal of cancer, 159(1), 257.

Jiang M, et al. (2026) HIF2A as a prognostic and clinical therapeutic target in ovarian clear cell carcinoma. International journal of cancer, 158(11), 2957.

Kawahara N, et al. (2025) Inhibition of glycolysis and stimulation of mitochondrial biogenesis lead to increased ROS levels and cell death in HNF-1 β positive clear cell carcinoma. Cell death & disease, 16(1), 879.

Sasaki M, et al. (2025) Efficacy of CBP/p300 Dual Inhibitors against Derepression of KREMEN2 in cBAF-Deficient Cancers. *Cancer research communications*, 5(1), 24.

Nie H, et al. (2025) Selective Alanine Transporter Utilization Is a Therapeutic Vulnerability in ARID1A-Mutant Ovarian Cancer. *Cancer research*, 85(18), 3471.

Little S, et al. (2025) Targeting SUMOylation in ovarian cancer: Sensitivity, resistance, and the role of MYC. *iScience*, 28(6), 112555.

Furutake Y, et al. (2024) YAP1 Suppression by ZDHHC7 Is Associated with Ferroptosis Resistance and Poor Prognosis in Ovarian Clear Cell Carcinoma. *Molecular cancer therapeutics*, 23(11), 1652.

Tsuchimochi S, et al. (2023) Characterization of a fluorescence imaging probe that exploits metabolic dependency of ovarian clear cell carcinoma. *Scientific reports*, 13(1), 20292.

Zhai T, et al. (2023) Combination therapy with bevacizumab and a CCR2 inhibitor for human ovarian cancer: An in vivo validation study. *Cancer medicine*, 12(8), 9697.

Liu C, et al. (2023) Cell-to-cell variability in Myc dynamics drives transcriptional heterogeneity in cancer cells. *Cell reports*, 42(4), 112401.

Zhou W, et al. (2023) Targeting the mevalonate pathway suppresses ARID1A-inactivated cancers by promoting pyroptosis. *Cancer cell*, 41(4), 740.

Handley KF, et al. (2023) Actionable spontaneous antibody responses antagonize malignant progression in ovarian carcinoma. *Gynecologic oncology*, 173, 114.

Köferle A, et al. (2022) Interrogation of cancer gene dependencies reveals paralog interactions of autosome and sex chromosome-encoded genes. *Cell reports*, 39(2), 110636.

Zundell JA, et al. (2021) Targeting the IRE1 α /XBP1 Endoplasmic Reticulum Stress Response Pathway in ARID1A-Mutant Ovarian Cancers. *Cancer research*, 81(20), 5325.

Kim J, et al. (2020) CDK7 is a reliable prognostic factor and novel therapeutic target in epithelial ovarian cancer. *Gynecologic oncology*, 156(1), 211.

Monchusi B, et al. (2017) Methyl pyruvate protects a normal lung fibroblast cell line from irinotecan-induced cell death: Potential use as adjunctive to chemotherapy. *PloS one*, 12(8), e0182789.